pharmaphorum

APRIL 12, 2022

The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of decline in the category. The Department of Health, NHS England and NICE have completed an evaluation of two new antibiotics – Pfizer’s Zavicefta (ceftazidime/avibactam) and Shionogi’s Fetcroja (cefiderocol) – that will be paid for using the new subscription-like model likened to a Netflix account.

119

119

Outsourcing Pharma

APRIL 12, 2022

A recent online event hosted by the patient services company invited a number of women to share their experience and insights working in the research field.

92

92

pharmaphorum

APRIL 12, 2022

Cate Evans, SVP group director, strategy at Havas Media Group, and Nick Lapolla, research director at MedSurvey tell us about a two-phase research study the companies recently performed to understand a patient’s prescription journey and who influences prescription-based decisions. The healthcare landscape has shifted dramatically due to the pandemic.

Communication 98

Communication Patient Care FDA 98

Outsourcing Pharma

APRIL 12, 2022

Miruna Sasu has been named president and CEO of the company, which uses RWD and analytics in advancing oncology drug development and clinical trial diversity.

81

81

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 12, 2022

Novartis has joined the select cadre of drugmakers developing KRAS inhibitors for cancer, opening its account with phase 1b data on JDQ443 showing efficacy in KRAS-mutated non-small cell lung cancer (NSCLC). The results – presented at the American Association of Cancer Research (AACR) congress – set Novartis off in pursuit of Amgen, whose Lumakras (sotorasib) is already on the market, and Mirati Therapeutics which has adagrasib under review by the FDA.

FDA 98

FDA 98

NICE

APRIL 12, 2022

Care models are changing all around us. The significant advancement of digital health technologies and artificial intelligence (AI) capabilities have the potential to revolutionise health and social care. A project within Gloucestershire Hospitals Trust is an excellent example of this. They used machine learning to identify patients at risk of avoidable long-term hospital stays.

Hospitals 52

Hospitals 52

Pharma Mirror

APRIL 12, 2022

There are so many ways to get into the healthcare industry these days. There are a lot of changes happening in the industry which means that there are a lot of niche services that you can provide and make a lot of money while also serving your communities needs. For instance, telehealth is a burgeoning field these days and is a good place to start. Another area that has a lot of potentials is starting a medical lab facility.

Medical Schools 52

Medical Schools 52

Pharma Marketing Network

APRIL 12, 2022

Tune in to this episode of the Pharma Marketing Podcast for a deeper dive into pharma and modular content, with Ryan Rosenberg, Director Omnichannel Capabilities @ Sanofi , who shared his insights on making modular content work and why pharma is the perfect candidate for it. The post Ep. 21: Pharma & Modular Content: A Deeper Dive appeared first on Pharma Marketing Network.

52

52

pharmaphorum

APRIL 12, 2022

Wherever you consider the medical industry, you will find several new technologies being used to make new medicines, vaccines, and fight illnesses. The purpose is to make our lifestyle better and healthier. The last two decades have been revolutionary for the healthcare industry. While many tech firms have applied their expertise to find solutions to the global pandemic, others have turned attention to using technology to transform healthcare services and products.

Vaccines 52

Vaccines 52

Pharma Times

APRIL 12, 2022

Novacyt’s second direct-to-PCR test is the third product to be added to the Coronavirus Test Device Approvals (CTDA) register of approved products

39

39

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

APRIL 12, 2022

Gilead Sciences can restart pivotal trials of its cancer antibody magrolimab – the centrepiece of its $4.9 billion acquisition of Forty Seven in 2020 – after the FDA relaxed its partial clinical hold on the studies. The US regulator implemented the restrictions on trials of magrolimab given in combination with Bristol-Myers Squibb’s Vidaza (azacitidine) in January, after seeing an “imbalance” in serious adverse events between study arms.

FDA 52

FDA 52

Pharma Times

APRIL 12, 2022

Engetix and Takeda will extend existing agreement to collaborate extensively in the development of therapeutics in IBD

42

42

pharmaphorum

APRIL 12, 2022

LazyCo, the wearables company behind the Aina Ring that can be used to interface with a smartphone, has been snapped up by digital fitness and wellness company Ultrahuman. Ultrahuman has developed an app-based platform for Apple and Android devices that combines workouts, mindfulness and sleep together into a single digital toolkit, available for an annual subscription fee, that can integrate with consumer wearables like the Apple Watch.

Communication 52

Communication 52